Public-registry site landscape for NCT05769608, “A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen”, a Hypertension study sponsored by Mineralys Therapeutics Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05769608 (registry record) |
| Study title | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
| Official title | A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen |
| Sponsor | Mineralys Therapeutics Inc. |
| Condition(s) | Hypertension |
| Phase | PHASE2 |
| Listed sites | 104 |
| Intervention(s) | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05769608.
Eichor generates a preliminary site-risk snapshot for NCT05769608 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
